Reference

CEM_CMO(2022)018

Name

Interleukin-6 inhibitors (tocilizumab or sarilumab) for adult patients hospitalised due to COVID-19

Categories

Scottish Government CMO Letters

Organization

Scottish Government Health and Social Care Directorates

Keywords

NHS SCOTLAND COVID-19 CORONAVIRUS TREATMENTS DRUGS PATIENTS HOSPITALS HEALTHCARE PROFESSIONALS ADULTS

Description

Please see the attached CMO letter, Interim Clinical Commissioning Policy and guidelines regarding the use of Interleukin-6 inhibitors (tocilizumab or sarilumab) for adult patients hospitalised due to COVID-19.

Contact Name

Irene Fazakerley

Contact Email

Contact Address

Contact Phone

Created

2022-11-29 00:00:00

Download URL